ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market .. DelveInsight ...Middle East

Approximately a year after the FDA rejected its previous approval submission, Abeona announced that the agency had approved ZEVASKYN, its autologous cell-based gene therapy for both adult and pediatric patients with RDEB. This approval marks Abeona's entry into the commercial gene therapy...

Read More Details
Finally We wish PressBee provided you with enough information of ( ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market .. DelveInsight )

Also on site :

• Diddy Trial Recap: Kid Cudi Testifies About Home Break-In and Porsche Molotov Cocktail Explosion
• Inside Mercedes-Benz’s plans to create a new HQ with hundreds of jobs in Atlanta
• Jenna Bush Hager Gives a 'Clue' About Her Next 'Surprise' Guest Host